Novavax gets a new CEO

Rockville-based Novavax has announced that Stanley Erck, its former executive chairman, is taking over as the company's new CEO. Prior to joining Novavax, Erck was CEO of Iomai Corporation, which went public and eventually merged with Intercell. Erck is replacing Rahul Singhvi, who served as the company's CEO for six years. Novavax didn't explain why the change was made, but a board member said the company wishes Singhvi, "nothing but the best in his future endeavors." HHS recently granted the developer a contract worth up to $179.1 million to fund research on seasonal and pandemic influenza vaccines. Release

Suggested Articles

The scientific community has again been caught off guard and industry officials are talking about implementing better preventive measures.

Sanofi didn't hesitate to enter Zika vaccine R&D, and despite the associated scandal, the company is again jumping into emerging disease vaccine R…

NIH and Moderna will need a coronavirus vaccine manufacturer, and and no major pharmaceutical company has stepped up.